Repligen stock snapshot and recent performance Repligen (RGEN) has drawn investor attention after recent trading left the shares around US$117.78, with the stock showing mixed returns over the past ...

Repligen (NASDAQ:RGEN) executives outlined a strategy focused on portfolio breadth, innovation, and commercial execution ...

NEW YORK (Reuters) -Repligen, a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings, a vaccine capping reagent vendor that has a market value of about $2.5 billion, ...

Repligen Corp (NASDAQ:RGEN) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents. The bioprocessing technology reported sales of ...

A month has gone by since the last earnings report for Repligen (RGEN). Shares have lost about 13.5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up ...

WALTHAM, Mass., June 22, 2021 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it has entered into ...

FOOTNOTES FOR ALL TABLES ABOVE (amounts in thousands): (1) In July 2023, we began restructuring activities to simplify and streamline our organization and strengthen the overall effectiveness of our ...

Avitide, a company that spun out of an Ivy League lab with a way to quickly and efficiently purify biologic drugs, is being acquired for $150 million by global bioprocessing vendor Repligen, which ...

Repligen is set to release its first-quarter earnings next Tuesday. Demand for its COVID-related products is declining, and investors appear to be bracing for the company to miss Wall Street's ...